The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

One of the platforms recently attracting global biopharmaceutical companies is the ‘Blood-Brain Barrier (BBB) Shuttle.’ The ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

Patent cliffs are forcing Big Pharma to hunt for revenue-producing biotech assets, and three names keep surfacing in deal ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

AbbVie proved big pharma will pay up for late-stage immunology, and three names keep surfacing on Wall Street's who’s-next ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

The new outfit, called Saturnus Bio, was announced today by Merck KGaA, and will focus on developing medicines for rare ...